title: [Sentinel node biopsy in breast cancer. Improving reliability of results].
abstract: OBJECTIVE
  Sentinel node (SN) biopsy in breast cancer has a relatively high false negative rate, frequently exceeding 10%, for predicting the axillary nodal status. When the SN is identified using the patent blue dye technique, we advocate subjecting it to a verification of its blue colour by the pathologist as quality control.
  
  
  METHODS
  One hundred and twenty-two consecutive patients with an operable breast cancer underwent a SN biopsy procedure with patent blue dye injected peritumourally. The SN biopsy was routinely followed by an axillary dissection. Initially each SN was examined histopathologically in a standard fashion. Then the non metastatic SNs were checked to ensure that they were blue by macroscopic examination of the paraffin blocks in which they had been embeded. Finally, a search for micrometastasis using immunohistochemistry was performed on all SNs which were non metastatic and confirmed to be blue.
  
  
  RESULTS
  In 107 (88%) of 122 patients a SN was identified by the surgeon. After standard histological examination, 32 of 107 SNs proved to contain metastatic tumour. 75 SNs were not metastatic, of which 3 were false negative which would have given a false negative rate of 8.5%(3/35). After checking the paraffin blocks of the 75 non metastatic SN, 62 of the 75 were confirmed blue from which there were 2 false negatives giving a false negative rate of 5.8% (2/34). The 62 confirmed blue nodes were then assessed for micrometastasis. 20 nodes proved to be micrometastatic and there remained one false negative. This gave a final false negative rate of 1.8% (1/53). The false negative rate was thus reduced from 8.5% to 1.8% after colour quality control and identification of micrometastasi.
  
  
  CONCLUSIONS
  In this series the procedure of histopathological quality control of the SN identified with the patent blue only technique resulted in a valuable reduction in the false negative rate.
authors.affiliation: Service de Chirurgie générale et sénologique, Institut Curie, Paris. claude.nos@curie.net
authors.forename: C
authors.initials: C
authors.lastname: Nos
authors.forename: P
authors.initials: P
authors.lastname: Freneaux
authors.forename: C
authors.initials: C
authors.lastname: Louis-Sylvestre
authors.forename: X
authors.initials: X
authors.lastname: Sastre-Garau
authors.forename: K B
authors.initials: KB
authors.lastname: Clough
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001943:Breast Neoplasms / Q000473:pathology*; D004396:Coloring Agents; D005188:False Negative Reactions; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008207:Lymphatic Metastasis / Q000175:diagnosis*; D008875:Middle Aged; D015588:Observer Variation; D015203:Reproducibility of Results; D021701:Sentinel Lymph Node Biopsy / Q000592:standards*
chemical_list: D004396:Coloring Agents